Axsome Therapeutics, Inc. - Common Stock (AXSM)

Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.

The stock slipped about 15% over the past three months.

One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.

Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

The company has also crushed broader equities over the past five years.

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 46.84% on an annualized basis producing an average annual return of 58.59%. Currently, Axsome Therapeutics has a market

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an annualized basis producing an average annual return of 40.19%. Currently, Axsome Therapeutics has a market

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.

Axsome Therapeutics (NASDAQ:AXSM) reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build. The company posted a net loss of $51.3 million, or $0.99 per share, comp

These innovative biotech companies should reap the benefits of their breakthroughs.

Sometimes, little-known stocks are worth buying.

These stocks both scored a win in the first half of the year.

These stocks have jumped in the double- and triple-digits.

The stock has soared more than 220% in three years.

All three could become highly prominent biotech companies within 10 years.

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive disorder and advance a broad central nervous system pipeline. Speaking at a Jefferies fireside chat

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive disorder, citing broad payer access, a larger sales force and what they described as a differentiated clin

The old healthcare model is breaking down.

These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.

Investors think a new addition to the biotech's pipeline could be the next catalyst.

Axsome (AXSM) Q1 2026 Earnings Call Transcript

Axsome (AXSM) Q2 2025 Earnings Transcript

Axsome (AXSM) Q1 2025 Earnings Call Transcript